Rainer J. Klement; Reinhart A. Sweeney
Single arm with 6 participants: Our data lend support to the hypothesis that KDs administered as supportive measures during standard therapy are safe and might be helpful in preservation of muscle mass. There was consensus that the KD was satiating and weight loss occurred in all patients, although this was only significant in two patients. Our data indicate that weight loss was mainly due to fat mass loss with concurrent preservation of muscle mass. Overall quality of life remained fairly stable, and all subjects reported feeling good on the diet. Tumor regression occurred as expected in five patients with early stage disease
Jocelyn Tan-Shalaby; Roby Antony Thomas; Jennifer Carrick; Andrew D. Liman; Vida Almario Passero; Arisha Patel; Jenna Shields
Single arm prospective with 3 participants: Ketogenic diets in human lymphomas appears well tolerated and can improve symptoms, quality of life, and limit tumor growth. Ketogenic diets may reverse the weight loss seen in terminal cancer patients with cachexia
Jocelyn L. Tan-Shalaby; Jennifer Carrick; Krystal Edinger; Dana Genovese; Andrew D. Liman; Vida A. Passero; Rashmikant B. Shah
Single arm prospective with with 17 participants: Dysfunctional mitochondrial processes limit malignant cells ability to use energy from fatty acids and ketones. Animal studies using ketogenic diets for cancer show encouraging results. We tested the diet’s safety and feasibility in cancer patients across a broad variety of solid tumors.
Ahmed M. A. Elsakka; Mohamed Abdel Bary; Eman Abdelzaher; Mostafa Elnaggar; Miriam Kalamian; Purna Mukherjee; Thomas N. Seyfried
Case Report: A press-pulse therapeutic strategy was implemented to target glucose and glutamine availability in a 38-year-old GBM patient using a modified SOC and KMT. As less than 20% of younger adults generally survive beyond 24 months with GBM, it is possible that the response observed in this case resulted in part from KMT and the modified SOC. The patient is now 40 years old and remains in excellent health with no noticeable neurological issues (Karnofsky Score, 100%) after 24 months of treatment.
Mehmet Salih İyikesici; Abdul Kadir Slocum; Ayshe Slocum; Ferhan Bulent Berkarda; Miriam Kalamian; Thomas N. Seyfried
Case Report: We have described a complete response to MSCT, KD, HT, and HBOT in a 29-year-old woman with stage IV (T4N3M1) TNBC that had metastasized to the lymph nodes, liver, and abdomen. Despite the advanced stage of this disease, the therapeutic strategy of combining MSCT, KD, HT, and HBOT achieved a clinical and radiological complete response in this patient within four months. The treatment regimen was continued for an additional two months when pCR was further documented in tissue following her mastectomy.
Juliana Guimarães Santos; Wanise Maria Souza Da Cruz; Axel H. Schönthal; Marcela D'alincourt Salazar; Cristina Asvolinsque Pantaleão Fontes; Thereza Quirico-Santos; Clovis Orlando da Fonseca
Case Report: After 3 months of a Ketogenic Diet combined with intra-nasal POH therapy led to a marked reduction of the lesion and significant clinical improvement. Tumor growth was halted during the 3-month treatment phase.
Cynthia A. Thomson; Alison T. Stopeck; Jennifer W. Bea; Ellen Cussler; Emily Nardi; Georgette Frey; Patricia A. Thompson
RCT with 40 Participants: A group of overweight female breast cancer survivors were assigned either a low-fat diet or Modified Atkins Diet. All subjects demonstrated improvements in total/HDL cholesterol ratio, and significant reductions inHbA1c, insulin, and HOMA. Triglycerides levels were significantly reduced only in the low-carbohydrate diet group. Significant improvements in weight and metabolic indexes can be demonstrated among overweight breast cancer survivors adherent to either the Modified Atkins Diet or fatrestricted diet.
Nebeling LC, Miraldi F, Shurin SB, Lerner E.
Establish dietary-induced ketosis in pediatric oncology patients to determine if a ketogenic state would decrease glucose availability to certain tumors, thereby potentially impairing tumor metabolism without adversely affecting the patient’s overall nutritional status.